Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bryan Dirks

Showing results (11-20 of 36) with videos related to

Pageof 4
Sort By:
Journal of Child and Adolescent Psychopharmacology|August 20, 2013
Treatment outcomes with lisdexamfetamine dimesylate in children who have attention-deficit/hyperactivity disorder with emotional control impairmentsAlain Katic, Bryan Dirks, Thomas Babcock, et al.
Journal of Clinical Psychopharmacology|October 14, 2014
Safety and pharmacokinetics of lisdexamfetamine dimesylate in adults with clinically stable schizophrenia: a randomized, double-blind, placebo-controlled trial of ascending multiple dosesPatrick Martin, Bryan Dirks, Lev Gertsik, et al.
Journal of Clinical Psychopharmacology|January 6, 2012
Sex subgroup analysis of treatment response to lisdexamfetamine dimesylate in children aged 6 to 12 years with attention-deficit/hyperactivity disorderJames J McGough, Michael Greenbaum, Ben Adeyi, et al.
Current Medical Research and Opinion|March 29, 2011
Long-term treatment outcomes with lisdexamfetamine dimesylate for adults with attention-deficit/hyperactivity disorder stratified by baseline severityLawrence Ginsberg, Alain Katic, Ben Adeyi, et al.
Current Medical Research and Opinion|October 7, 2011
Clinical utility of ADHD symptom thresholds to assess normalization of executive function with lisdexamfetamine dimesylate treatment in adultsThomas E Brown, Matthew Brams, Maria Gasior, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 25, 2025
Drug DevelopmentMona Darwish, Jay W Mason, Stephanie W Stanworth, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|August 2, 2018
Distinguishing the efficacy and sedative effects of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorderMichael Huss, Keith McBurnett, Andrew J Cutler, et al.
Psychopharmacology Bulletin|November 7, 2022
Adjunctive Pimavanserin in Patients with Major Depressive Disorder: Combined Results from Two Randomized, Double-Blind, Placebo-Controlled Phase 3 StudiesBryan Dirks, Maurizio Fava, Sarah D Atkinson, et al.
Journal of Attention Disorders|June 29, 2012
The effects of lisdexamfetamine dimesylate on emotional lability in children 6 to 12 years of age with ADHD in a double-blind placebo-controlled trialAnn C Childress, Valerie Arnold, Ben Adeyi, et al.
Journal of Child and Adolescent Psychopharmacology|February 16, 2013
Parent-reported executive function behaviors and clinician ratings of attention-deficit/hyperactivity disorder symptoms in children treated with lisdexamfetamine dimesylateRobert L Findling, Ben Adeyi, Bryan Dirks, et al.
Pageof 4

Showing results (11-20 of 36) with videos related to

Sort By:
Pageof 4
Journal of Child and Adolescent Psychopharmacology|August 20, 2013
Treatment outcomes with lisdexamfetamine dimesylate in children who have attention-deficit/hyperactivity disorder with emotional control impairmentsAlain Katic, Bryan Dirks, Thomas Babcock, et al.
Journal of Clinical Psychopharmacology|October 14, 2014
Safety and pharmacokinetics of lisdexamfetamine dimesylate in adults with clinically stable schizophrenia: a randomized, double-blind, placebo-controlled trial of ascending multiple dosesPatrick Martin, Bryan Dirks, Lev Gertsik, et al.
Journal of Clinical Psychopharmacology|January 6, 2012
Sex subgroup analysis of treatment response to lisdexamfetamine dimesylate in children aged 6 to 12 years with attention-deficit/hyperactivity disorderJames J McGough, Michael Greenbaum, Ben Adeyi, et al.
Current Medical Research and Opinion|March 29, 2011
Long-term treatment outcomes with lisdexamfetamine dimesylate for adults with attention-deficit/hyperactivity disorder stratified by baseline severityLawrence Ginsberg, Alain Katic, Ben Adeyi, et al.
Current Medical Research and Opinion|October 7, 2011
Clinical utility of ADHD symptom thresholds to assess normalization of executive function with lisdexamfetamine dimesylate treatment in adultsThomas E Brown, Matthew Brams, Maria Gasior, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 25, 2025
Drug DevelopmentMona Darwish, Jay W Mason, Stephanie W Stanworth, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|August 2, 2018
Distinguishing the efficacy and sedative effects of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorderMichael Huss, Keith McBurnett, Andrew J Cutler, et al.
Psychopharmacology Bulletin|November 7, 2022
Adjunctive Pimavanserin in Patients with Major Depressive Disorder: Combined Results from Two Randomized, Double-Blind, Placebo-Controlled Phase 3 StudiesBryan Dirks, Maurizio Fava, Sarah D Atkinson, et al.
Journal of Attention Disorders|June 29, 2012
The effects of lisdexamfetamine dimesylate on emotional lability in children 6 to 12 years of age with ADHD in a double-blind placebo-controlled trialAnn C Childress, Valerie Arnold, Ben Adeyi, et al.
Journal of Child and Adolescent Psychopharmacology|February 16, 2013
Parent-reported executive function behaviors and clinician ratings of attention-deficit/hyperactivity disorder symptoms in children treated with lisdexamfetamine dimesylateRobert L Findling, Ben Adeyi, Bryan Dirks, et al.
Pageof 4